Dear Sirs, Intravenous tissue plasminogen activator (tPA) thrombolysis remains the only proven pharmacological treatment for acute ischemic stroke [1] . A common clinical scenario is where a patient with atrial fibrillation (AF) on therapeutic anticoagulation presents with an acute ischemic stroke but thrombolysis is absolutely contraindicated due to hemorrhagic risk.
Recently, dabigatran reversal with idarucizumab to facilitate thrombolysis in acute stroke patients on dabigatran has been proposed [2] . We present two patients, the first outside Europe, managed with this approach (Fig. 1) .
Case 1 A well 85-year-old presented with a severe dominant hemispheric stroke with a National Institutes of Health Stroke Scale (NIHSS) of 30 within 17 h of last dabigatran dose. Computed Tomography (CT) with angiogram and perfusion studies showed a tandem left Internal Carotid Artery and Middle Cerebral Artery (ICA-MCA) occlusion with minimal established infarction and a large salvageable penumbra. Coagulation studies revealed isolated elevated Thrombin Time ([60 s, normal range \21 s) consistent with active dabigatran anticoagulation. 5 g of idarucizumab followed by tPA were administered at 167 min from symptoms onset. Mechanical thrombectomy was not possible as the patient arrived at an endovascularcapable centre outside the 6 h therapeutic time window after urgent inter-hospital transfer post-thrombolysis. Day-1 CT showed a large hemispheric infarct with significant hemorrhage and mass effect. He progressively deteriorated and died on day 4.
Case 2 A 46-year-old with AF presented with left hemiparesis (admission NIHSS 5) within 1 h of dabigatran intake. Multimodal CT revealed a right frontal ischemic penumbra without large vessel occlusion or stenosis. Idarucizumab and immediate tPA were administered at 178 min from onset with near-total resolution of symptoms (NIHSS 1). Follow-up CT confirmed a small area of right frontal infarction. At 30 h, he developed a severe contralateral left hemispheric stroke (NIHSS 18) secondary to a left M2 segment MCA thrombus which was too distal for endovascular clot retrieval. With the recent stroke contraindicating further thrombolysis, he was conservatively treated. Subsequent echocardiogram did not reveal intracardiac thromboses or valvular lesions. He remained aphasic and bed-bound for 3 months.
Idarucizumab, a humanised monoclonal antibody fragment, was approved by the European Medicine Agency in 2015 as a reversal agent in patients on dabigatran requiring emergency procedures, or with life-threatening bleeding [3] . In-vitro and in vivo studies with healthy controls have shown immediate normalization of dabigatran-induced anticoagulation following idarucizumab without prothrombic effects [4, 5] . Based on these results, idarucizumab-facilitated thrombolysis in dabigatran-treated stroke patients has been endorsed by international expert opinion. However, real-world clinical data are sparse with only six cases described [3, [6] [7] [8] [9] [10] , with the majority reporting favorable clinical outcomes without complications ( Table 1) . The patients reported here have inherent risk factors for their adverse events irrespective of idarucizumab use. The high NIHSS and presence of major arterial occlusion in case 1 predispose to hemorrhagic transformation [11] , while the increased risk of early stroke recurrence is well recognized in patients with cortical infarcts and AF as in case 2 [12] . Although we acknowledge there is insufficient information to conclude whether idarucizumab directly contributed to the adverse outcomes, the development of both major hemorrhage and recurrent thrombo-embolism in two of the eight reported cases of idarucizumab-facilitated thrombolysis to date is nonetheless noteworthy.
Further studies are needed to evaluate the risks and benefits of idarucizumab-facilitated thrombolysis before this approach is universally adopted. Previously published cases have generally had good outcomes though this could in part reflect publication bias. The authors strongly recommend the establishment of an international clinical registry to monitor outcomes in idarucizumab-facilitated thrombolysis to ensure that this potentially invaluable therapy is safe and effective in clinical practice.
Case 1 presented with acute left tandem ICA-MCA occlusion as shown on non-contrast CT with hyperdense MCA sign (arrow) and on CTA (b). Day-1 post thrombolysis CT showed large left hemispheric infarct with significant hemorrhage (c and d). Case 2 presented with left hemiparesis with right frontal ischemic penumbra (arrow) on perfusion CT (e). Right frontal evolving infarct (arrow) was seen at 24-h post-thrombolysis (f). Contralateral stroke recurrence developed at 30-h with distal MCA hyperdense sign (arrow). Follow-up CT showed established left frontal infarct.
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